Skip to main content

J&J: Potential HIV vaccine falls short in mid-stage study

This Feb. 24, 2021 photo shows a Johnson & Johnson logo on the exterior of a first aid kit in Walpole, Mass. (AP Photo/Steven Senne, file) This Feb. 24, 2021 photo shows a Johnson & Johnson logo on the exterior of a first aid kit in Walpole, Mass. (AP Photo/Steven Senne, file)
Share

A potential HIV vaccine being developed by Johnson & Johnson did not provide protection against the virus in a mid-stage study, the drugmaker said Tuesday.

J&J plans to end that study, which involved young women in sub-Saharan Africa. But researchers will continue a separate, late-stage trial involving a different composition of the vaccine in men and transgender people.

The study in sub-Saharan Africa involved about 2,600 women who were deemed to be at high risk of acquiring HIV, which causes AIDS. Participants were randomly selected to receive either the vaccine or a placebo, and researchers found that the vaccine was only 25 per cent effective at preventing HIV.

"HIV is a unique and complex virus that has long posed unprecedented challenges for vaccine development because of its ability to attack, hijack and evade the human immune system," J&J Chief Scientific Officer Dr. Paul Stoffels said in a statement.

J&J said its other study of the potential vaccine is being conducted in Europe and the Americas, where different strains of HIV are circulating.

New Brunswick, New Jersey-based Johnson & Johnson also makes one of the three vaccines approved by U.S. regulators for the prevention of COVID-19. J&J also is developing vaccines for sepsis and respiratory syncytial virus.

CTVNews.ca Top Stories

opinion

opinion Joe Biden uses bully pulpit to bully Donald Trump on debates

Donald Trump had spent weeks needling U.S. President Joe Biden for his refusal to commit to a debate. But Washington political columnist Eric Ham describes how in one fell swoop, Biden ingeniously stole the issue from the Trump campaign and made it his own.

Local Spotlight